Citations

Clear

4610 citation(s) found for "Lu, Brian".

Individualized neoantigen vaccine with nivolumab plus cabozantinib for translocation renal cell carcinoma: Single patient investigational new drug.
Kase, Adam M. , Tan, Winston , Copland, John A. , Gustafson, Michael P. , Asmann, Yan W. , Necela, Brian M. , Knutson, Keith L. , Knutson, Keith L.

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 537-537

10.1200/jco.2025.43.5_suppl.537 Get It

537 Background: Translocation renal cell carcinoma (tRCC) is a rare renal cell carcinoma subtype found in about 1-4% of adult patients with RCC and 40% of pediatric RCC cases. Management of advanced tRCC has been guided by clear cell RCC therapy and retrospective reviews which include tRCC cohorts. Novel therapeutic strategies are needed to improve outcomes. This study assessed an individualized neoantigen vaccine with nivolumab plus cabozantinib in a patient with metastatic TFE3-tRCC. Methods: Patient was consented (IRB# 20-011945) for a single-patient investigational new drug (IND#27755). In-house neoantigen prediction bioinformatics pipeline (REAL-neo v2.0) was performed to identify and prioritize neoantigen candidates. Patient underwent lymphodepletion with cyclophosphamide followed by vaccine administration on days 1, 4, 8, 11, 20, 40, week 12, and week 20. Patient was also treated with concurrent nivolumab 480 mg every 4 weeks and cabozantinib 40 mg daily. Objective response rate (ORR) and progression-free survival (PFS) were measured. Results: Patient was diagnosed with TFE3-tRCC and underwent nephrectomy prior to developing metastatic disease. He was treated with multiple liver surgeries, ablations, and radiation therapy without systemic therapy. This controlled his disease for 7 years before he required systemic therapy with ipilimumab plus nivolumab. After 4 cycles, imaging showed progression and was started on cabozantinib which controlled his disease for 1 year. Patient was consented for the neoantigen vaccine. Cycle 1 was administered in April 2022. Three liver lesions and 1 periportal lymph node were monitored. After 4 months of therapy, imaging showed partial response with 34% decrease in sum of target lesions. In June 2023, partial response was ongoing with a 57.4% decrease. A 2 nd vaccine series was administered in June 2023 and had stable disease until progression in June 2024 when patient held his cabozantinib for at least 4 weeks. Neoantigen combination therapy achieved a progression-free survival of 26 months and was well tolerated without significant vaccine-related adverse events. Conclusions: Individualized neoantigen vaccine plus nivolumab and cabozantinib achieved a durable partial response with prolonged progression-free survival. A randomized clinical trial is warranted to further evaluate the efficacy of this combination therapy.
Olanzapine for managing side effects from tyrosine-kinase inhibitors.
Koch, Regina M. , Muniz, Miguel, Peskey, Candy S , Jatoi, Aminah , Ruddy, Kathryn J. , Orme, Jacob J. , Pagliaro, Lance C. , Quevedo, Fernando , Costello, Brian A. , Spychalla, Megan, Heath, Elisabeth I. , D’Andre, Stacy D. , Loprinzi, Charles L. , Zakharia, Yousef , Singh, Parminder Pal , Riaz, Irbaz Bin , Cathcart-Rake, Elizabeth , Childs, Daniel S.

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 524-524

10.1200/jco.2025.43.5_suppl.524 Get It

524 Background: Antiangiogenic tyrosine kinase inhibitors (TKIs) play a key role in treating renal cell carcinoma and other solid organ malignancies, but TKIs cause bothersome side effects that frequently necessitate dose reductions or treatment holds. Olanzapine has been useful for palliating symptoms from classical chemotherapies and advanced cancer, but its effect on TKI-related symptoms is largely unknown. This retrospective study aimed to estimate the efficacy of olanzapine for TKI-induced nausea, vomiting, anorexia, weight loss, and insomnia. Methods: All patients prescribed olanzapine with lenvatinib, cabozantinib, axitinib, or tivozanib at Mayo Clinic between January 1, 2018, and June 30, 2024 were assessed for inclusion. For baseline symptom assessment, clinical care team notes documenting the presence or absence of symptoms and indication(s) for starting olanzapine were reviewed. For response assessment, clinical notes and patient portal messages from the first three months after starting olanzapine were evaluated for qualitative descriptions of change in symptom burden. Relevant data were extracted as direct quotations, which were reviewed by the research team and categorized as “improved,” “worsened,” “stable,” or “missing data.” Each symptom domain was analyzed independently when olanzapine was prescribed for multiple interrelated symptoms. Results: A total of 60 patients who received olanzapine for the treatment of TKI-related adverse effects were included. The most common documented indication for olanzapine was nausea without vomiting (n=35), followed by anorexia (n=25), nausea with vomiting (n=16), weight loss (n=16), and insomnia (n=11). In 32 cases (53%), olanzapine was prescribed for multiple, simultaneous symptoms. Response rates for each symptom domain are shown in the table. In addition, prior to olanzapine, 34 patients (57%) had documented weight loss. Following olanzapine, 50% (n=17) gained weight (median increase: 6.1 kg; range: 2.0 - 10.7 kg), 26% (n=9) stabilized their weight (±1 kg), and 24% (n=8) continued to lose weight. Clinicians utilized a TKI dose reduction within one week of olanzapine initiation in 5 cases (8.3%), and 3 of these patients could resume the higher dose of TKI after starting olanzapine. Only 4 patients (7%) discontinued olanzapine within 3 months due to perceived side effects. Conclusions: Olanzapine appears to be effective in treating TKI-induced nausea, vomiting, anorexia, insomnia, and weight loss. Prospective randomized placebo-controlled studies are needed to confirm these findings. Improvedn (%) Worsened n (%) Stablen (%) Missing Datan (%) Nausea without emesis 32 (84) 3 (8) 1 (3) 2 (5) Nausea with emesis 13 (93) 0 (0) 0 (0) 1 (7) Anorexia 26 (74) 2 (6) 4 (11) 3 (9) Insomnia 11 (85) 0 (0) 2 (15) 0 (0)
Androgen suppression with abiraterone acetate, leuprolide, PARP inhibition, and stereotactic body radiotherapy (ASCLEPIuS) in high-risk and node positive prostate cancer (PCa): Phase I multicenter results.
Dess, Robert T. , Jia, Angela Y. , Desai, Neil , Reichert, Zachery R. , Marciscano, Ariel E. , Zuhour, Raed , García, Jorge A. , Mendiratta, Prateek, Feng, Felix Y. , Suresh, Krithika , Dess, Robert T , Jackson, Will , Nagar, Himanshu , Hannan, Raquibul , Hearn, Jason W.D. , Davis, Brian J. , Zaorsky, Nicholas G. , Barata, Pedro C. , Brown, Jason R. , Chinnaiyan, Arul , Spratt, Daniel E.

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 387-387

10.1200/jco.2025.43.5_suppl.387 Get It

387 Background: Level 1 evidence supports treatment of high-risk and node positive PCa using 4-9 weeks of radiotherapy (RT) combined with 18-36 months of androgen deprivation therapy (ADT) with or without abiraterone acetate plus prednisone (AAP). While effective, some cancers recur, and this prolonged treatment is associated with inconvenience and variable morbidity. We aimed to determine whether the biological synergy of stereotactic body radiotherapy (SBRT) with a 6-month combination of ADT, AAP, and the PARP inhibitor niraparib, could enable a shorter intensified, yet safe and effective, therapeutic alternative. Methods: ASCLEPIuS (NCT04194554) is a multicenter investigator-initiated phase I/II trial in high-risk or node positive, homologous recombination unselected, PCa. Patients received 6 months of ADT, AAP, niraparib and SBRT to the prostate (37.5-40 Gy) +/- pelvic lymph nodes (25 Gy). Focal prostate/nodal boosting was permitted. The phase I primary endpoint was the maximum tolerated dose (MTD) of niraparib using the time-to-event continuous reassessment method (3 dose levels: 100 mg and 200 mg held during SBRT, or 200 mg concurrent with SBRT). Dose limiting toxicities (DLT) were any persistent grade 4+ hematologic toxicity or any grade 3+ rectal/urinary toxicity at least possibly related to treatment as assessed by CTCAE v5.0. Patient reported quality of life (QOL) was assessed with the EPIC-26 short form. Linear mixed models were used to compare scores over time. Results: Accrual began in Nov. 2020 with a transition from phase I to phase II in May 2023 after enrolling 54 men. Median follow-up of the phase I cohort is 12.1 months (IQR 9.4-18.9), 80% (n=43) had Grade Group 4-5, median PSA was 17 ng/mL (range, 1-73), 15% (n=8) had cN+ disease, and 76% (n=41) received nodal RT. There were 0 DLTs to date, no grade 3+ rectal or urinary toxicities, and 5 serious adverse events at least possibly attributable to study treatment (anemia, non-rectal gastrointestinal, syncope, infection, musculoskeletal). The most common grade 3 toxicities were hypertension (n = 11, 21%) and leukopenia (n=6, 11%). Transient dose reductions or holds of AAP or niraparib occurred in 10 and 11 patients, respectively. There were no statistically significant declines in patient reported urinary QOL at 6- or 12-months post-treatment compared to baseline (all p >0.15). A transient decline in bowel QOL at 6-months occurred (p<0.01), which improved by 12-months (p=0.16). Conclusions: Our phase I findings support the short-term safety and tolerability of the combination of SBRT to the prostate and nodes, ADT, AAP, and niraparib at an MTD of 200 mg in men with high-risk or node positive PCa. Our trial completed phase II enrollment in May 2024, and longer-term safety, efficacy, and genomic correlations will be presented in the future. Clinical trial information: NCT04194554 .
AI-driven prediction of prostate cancer risk: A comparative analysis with C the Signs in the Mayo Clinic data platform.
Bakshi, Bea, Raoof, Sana , Haddad, Tufia C. , Ryan, Charles J. , Dadhania, Seema , Herrick, Brian, Payling, Miles, Patel, Tushar , Riaz, Irbaz Bin

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 371-371

10.1200/jco.2025.43.5_suppl.371 Get It

371 Background: Prostate cancer is the most common malignancy in men globally and remains among the top five leading causes of cancer-related deaths. Emerging evidence suggests that early identification of symptoms can detect localized disease thus enabling opportunities for curative intent treatments. This study evaluates the use of the AI-powered prediction model, C the Signs, to passively screen for prostate cancer by leveraging data from electronic medical records (EMRs), offering a novel pathway for identifying high-risk individuals. Methods: A retrospective analysis was conducted using the Mayo Data Platform, encompassing 418,477 male patient records, of which 16,835 were diagnosed with prostate cancer. C the Signs identified patients at risk based solely on their EMR data, utilizing AI-driven pattern recognition. Sensitivity and specificity analyses were performed to assess the prediction model’s accuracy. Additionally, we examined the time-to-diagnosis advantage for patients flagged by the model compared to traditional physician clinical diagnoses. Results: C the Signs demonstrated a sensitivity of 83.3% and a specificity of 52.5% for identifying patients at risk of prostate cancer. Notably, 31.8% of prostate cancer cases were identified at risk up to five years earlier by the model compared to traditional physician clinical diagnosis. Conclusions: The integration of AI-driven prediction models like C the Signs into prostate cancer screening pathways provides an opportunity to enhance early detection, particularly in symptomatic individuals. Compared to prostate-specific antigen (PSA) testing, the model achieved equivalent sensitivity and 38% higher specificity, positioning it as a valuable companion tool for improving patient outcomes.
Safety evaluation of stereotactic body radiation therapy (SBRT) during lutetium-177-PSMA-617 (177Lu-PSMA-617) treatment for patients with metastatic prostate cancer.
Kessel, Adam , Muniz, Miguel, O'Byrne, J, Phillips, Ryan , Park, Sean Sunghun, Stish, B.J., Choo, Chunhee Richard, Merrell, Kenneth W. , Kwon, Eugene D., Orme, Jacob J. , Wilson, Jessica , O'Byrne, Jamie T, Davis, Brian J. , Johnson, Geoffrey B. , Quevedo, Fernando , Childs, Daniel S.

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 129-129

10.1200/jco.2025.43.5_suppl.129 Get It

129 Background: Few studies have explored the use of focal therapies to address select sites of resistant disease in men receiving 177-Lu-PSMA-617 for metastatic castrate resistant prostate cancer (mCRPC). Our institutional practice is to offer SBRT for patients with up to 5 sites of oligoprogression or non-responding lesions while undergoing 177Lu-PSMA-617 (every 6 weeks for 6 cycles total). This is determined by PSMA or choline PET imaging during the course of 177Lu-PSMA-617. Herein, we evaluated the safety of adding target SBRT during treatment with 177Lu-PSMA-617. Methods: This retrospective single institution analysis was conducted via systematic chart review to evaluate for adverse events during or after treatment. Grading of treatment-related adverse events was conducted using Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5). Results: Thirty-one patients receiving 177Lu-PSMA-617 with 51 sites of oligoprogressive or non-responding metastatic disease were treated with SBRT. The median number of sites treated was 1 (range 1-4). Most patients received SBRT immediately after cycle 6 (32%) or after cycle 3 or 4 (42%). Bone was the most commonly treated site of disease (90%) with the majority (54%) of bone sites being spine or sacrum, followed by lymph nodes (10%). Ultimately, 84% of patients completed all 6 cycles of 177Lu-PSMA-617 (range 4-6). The median follow-up time was 19.1 months (IQR 15.5-22.4) after 177Lu-PSMA-617 therapy start. A total of 2 patients experienced a pathologic fracture within the SBRT treatment field that could possibly be related to radiotherapy. One patient experienced a grade 2 neuropathy which may have been related to radiation therapy. Other potential adverse events are listed (Table). Conclusions: Our data demonstrates a low rate of significant toxicity with the use SBRT during treatment with 177Lu-PSMA-617. Further study is indicated to determine the oncologic efficacy and potential late side effects of this treatment strategy. Adverse events. Event All Grades Grade > 3 Any Adverse Event 104 2 Anemia 29 (94%) 0 Low Platelets 11 (35.5%) 1 (3.2%) Any Pathologic Fracture 7 (22.5%) 1 (3.2%) Possible SBRT-related Pathologic Fracture 2 (6.5%) 1 (3.2%) Bone Pain Flare 3 (9.6%) 0 Neuropathy 1 (3.2%) 0
PSA dynamics: Enhancing predictive models in prostate cancer follow-up.
Ekama, Lydia, Osorio, Mariana Borras, Bogan, Aaron, Comstock, Bryce, Talom, Benjamin K., Weiskittel, Taylor M. , Griner, Dalton , Stish, B.J., Choo, Chunhee Richard, Phillips, Ryan, Pisansky, Thomas M. , Waddle, Mark R. , Namazi, Mohammad Javad , Davis, Brian J. , Ebner, Daniel, Routman, David M.

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 424-424

10.1200/jco.2025.43.5_suppl.424 Get It

424 Background: Advances in prostate cancer (PC) care have led to a 98% 10-year survival rate. Prostate Specific Antigen (PSA) is the primary method of follow-up after definitive radiotherapy (RT), with benign PSA ‘bounce’ occurring in up to 30% of patients, causing uncertainty and anxiety. Distinguishing between PSA bounce and biochemical recurrence (BCR) remains challenging. The Phoenix Criteria is the standard definition of BCR since 2006, defined as PSA nadir + 2 ng/dl, but does not consider patient specific information. Our study aims to explore factors associated with bounce and BCR and develop a predictive tool to differentiate between these two events. Methods: PC patients who received RT at our institution between 2006 and 2022 were identified, including only patients with a PSA increase during follow-up. Exclusion criteria included palliative RT, prostatectomy, or insufficient follow-up information. Patients’ clinical data was collected, and PSA increase was classified as bounce or BCR. Variables were compared using Kruskal Wallis or Chi-square. Multivariate logistic regression was performed in the subset of patients with absolute PSA value >2 (n= 581). Results: Of 1783 patients reviewed due to PSA rise after treatment, 694 met the inclusion criteria. There were 213 (30.7%) with PSA bounce and 481 (69.3%) with recurrence. Prior to meeting the Phoenix Criteria, 20 (4.2%) had biopsy-proven recurrence and 18 (3.7%) imaging-proven recurrence. The median delta PSA was 0.8 ng/mL for bounce vs 5 ng/mL for recurrence (p<0.001). The median time from treatment to event was 14.4 months for bounce vs 45.3 months for BCR (p<0.001). Recurrence was significantly associated (p<0.001) with older age at diagnosis, N1 stage, higher risk category, Gleason score, and higher baseline PSA. In the subgroup of patients without ADT, recurrence was associated with a lower median first PSA post-RT (1.9 vs. 2.4, p=0.046) and a lower median nadir before event (0.6 vs. 1.8, p<0.001). Multivariate logistic regression achieved an accuracy of 0.94, with a sensitivity of 0.83, specificity of 0.98, and an area under the curve (AUC) of 0.97. Conclusions: Our results highlight significant differences in clinical factors between bounce and recurrence in post-RT patients. The multivariate logistic regression differentiated the events with 94% accuracy for patients with a rising PSA value >2 subgroup. We highlight the possible improvement that could be accomplished by personalizing a PSA threshold for recurrence versus the Phoenix definition. This tool offers patients and providers a highly specific tool to differentiate between PSA recurrence and bounce, and may reduce stress and unnecessary testing, or help diagnosis recurrence faster. Next steps include prospective validation of the model to assess the impact on clinical practice costs, patient experience, and cancer outcomes.
Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis—The Time Has Come
Braunwald, Eugene, Lindman, Brian R. , Braunwald, Eugene , Pellikka, Patricia A.

Mayo Clinic

JAMA Cardiology | February 12, 2025 | Volume: 10 | Issue: 4 | Pages: 305

10.1001/jamacardio.2024.5648 | PMID 39937467 Get It

This Viewpoint advocates for prompt aortic valve replacement (rather than clinical surveillance) as the default strategy for patients with asymptomatic severe aortic stenosis.
Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
Shi, Qian , Paiva, Bruno , Pederson, Levi , Dimier, Natalie , Talpes, Ela, Prior, Thomas J. , Órfão, Alberto , Sonneveld, Pieter , Kumar, Shaji , Patel, Reshma, Bartlett, Blake, Schecter, Jordan M. , Seckinger, Anja , D’Agostino, Mattia , Goldschmidt, Hartmut , Owen, Roger G., Durie, Brian G.M. , Munshi, Nikhil C. , Group, on behalf of the International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM), Pederson, Levi D , Moreau, Philippe , Sonneveld, Pieter , Kumar, Shaji K , Dixon, Jesse G. , McCarthy, Phillip , Hose, Dirk , Seckinger, Anja , Mattia, D'Agostino , Goldschmidt, Hartmut , Oliva, Stefania , Anderson, Kenneth C , San-Miguel, Jesus , Munshi, Nikhil C , Shi, Qian , Paiva, Bruno , Orfao, Alberto , Moreau, Philippe , Patel, Reshma, McCarthy, Philip L. , Hose, Dirk , Oliva, Stefania , Anderson, Kenneth C. , Miguel, Jesús F. San , Group, on behalf of the International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM)

Mayo Clinic

Journal of Clinical Oncology | February 12, 2025 | Volume: 43 | Issue: 11 | Pages: 1289-1301

10.1200/jco-24-02020 | PMID 39938021 Get It

PURPOSE Newly approved drugs and combinations treating multiple myeloma (MM) have resulted in substantial improvements in patients' survival. To deliver rapid access to newer therapies, an earlier end point to expedite clinical trials is needed. Our objective was to evaluate the minimal residual disease–negative complete response (MRD-CR) as an intermediate end point for progression-free survival (PFS) and overall survival (OS) in newly diagnosed (ND) transplant-eligible (NDTE) patients, ND transplant-ineligible (NDTinE) patients, and patients with relapsed/refractory (RR) MM. PATIENTS AND METHODS Individual patient data from 20 randomized multicenter trials were collected. Eleven studies (4,773 patients) with sufficient data were analyzed to evaluate whether 9- or 12-month MRD-CR classified at a 10 –5 threshold could be reasonably likely to predict the clinical benefit of new agents regarding PFS and OS. Global odds ratio (OR) was estimated using the bivariate Plackett Copula model. Supportive evaluation included correlations of the treatment effects on MRD-CR end points and PFS/OS, evaluated by both linear regression ( R 2 weighted least squared ) and Copula ( R 2 Copula ) models. RESULTS The analysis demonstrated that both 9- and 12-month MRD-CR strongly correlated with PFS at patient level in NDTE patients, NDTinE patients, and patients with RRMM. Global ORs ranged from 3.06 to 16.24, all with 95% CIs excluding 1.0. Encouraging trial-level correlations ( R 2 , 0.61-0.70) were observed by pooling three populations and were stronger ( R 2 , 0.67-0.78) in the ND population. Similar results were observed for OS. CONCLUSION Our findings provided the support for use of MRD-CR classified at a 10 –5 threshold at either 9 or 12 months after starting of the treatment, as an intermediate end point to support accelerated approvals, in future trials in NDTE patients, NDTinE patients, and patients with RRMM.
Endoconduit: Utilizing the “Pave-and-Crack” Technique to Treat an Abdominal Aortic Aneurysm—A Contemporary Literature Review, and “How We Do It”
Garner, Sydney , Alsabbagh, Yaman , Sorrentino, Mariano, Dahiya, Rockey , Vandenberg, Jonathan , Mahajan, Biraaj, Farres, Houssam , Anderson, Erik , Fazzone, Brian , Jacobs, Christopher R. , Dahiya, Rockey , Sorrentino, Mariano, Erben, Young , Anderson, Erik , Filiberto, Amanda C. , Jacobs, Christopher

Mayo Clinic

Journal of Vascular Diseases | February 12, 2025 | Volume: 4 | Issue: 1 | Pages: 6

10.3390/jvd4010006 Get It

We present an 81-year-old male with an extensive past medical history and an enlarging abdominal aortic aneurysm (AAA). Axial imaging showed dense aortoiliac calcification with a complete occlusion of the right common iliac and high-grade stenosis of the left common iliac artery (CIA). Shockwave Intravascular Lithotripsy and the pave-and-crack technique utilizing an endoconduit were used to dilate the left external iliac artery and the CIA to facilitate placement of an aortic stent graft and exclude the patient’s AAA. This method gives surgeons the ability to treat patients with AAAs endovascularly, despite a heavily diseased and/or diminutive iliac anatomy. We also present a contemporary literature review of the utilization of the pave-and-crack technique as well as tips and tricks of how we do it.
Epilepsy Surgery Education: A Survey of US Epilepsy Fellowship Program Directors
Katyal, Roohi , Gutierrez, Camilo , Day, Brian K., Gavvala, Jay R. , Sheth, Sameer A. , Gavvala, Jay R , Sheikh, Irfan , Sinha, Saurabh R. , Wirrell, Elaine , Beniczky, Sándor , Nascimento, Fábio A.

Mayo Clinic

Journal of Clinical Neurophysiology | February 12, 2025 | Volume: 43 | Issue: 1 | Pages: 1-8

10.1097/wnp.0000000000001144 | PMID 39934975 Get It

Purpose: To understand the current state of epilepsy surgery education delivered to epilepsy fellows in the United States. Methods: An online survey focused on characteristics of epilepsy surgery education was distributed to all 93 epilepsy fellowship program directors listed on the ACGME website (accessed in May 2022). Programs were stratified per the number of fellows currently enrolled: 0 to 3 (group A) and ≥4 (group B). Results: Forty-one of 93 (44%) epilepsy fellowship programs were included in the study. The average number of resective surgeries, ablations, or corpus callosotomies per year was mostly 0 to 30 (54%) in group A and mostly >30 (80%) in group B ( P = 0.05). The average number of intracranial implantations per year was mostly 0 to 20 (58%) in group A and mostly >20 (80%) in group B ( P < 0.05). The average number of neurostimulation implantations per year was 15 (range 0–90; vagal nerve stimulation), 7 (range 0–25; responsive neurostimulation), and 4 (range 0–10; deep brain stimulation). In 78% of programs, fellows are not required to present a minimum number of epilepsy surgery cases in multidisciplinary conference before graduation. Roughly half of programs (51%) reported not using objective measures to assess fellow competency in epilepsy surgery. Conclusions: Our results suggest significant variability in epilepsy surgery volume and, consequently, fellow exposure to surgical cases and lack of standardized, objective measures in fellow teaching and assessment in the field of epilepsy surgery across programs in the United States. We advocate development of a core epilepsy surgery curriculum including minimum standards at the national level.